BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22449730)

  • 21. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pirfenidone enhances the efficacy of combined radiation and sunitinib therapy.
    Choi SH; Nam JK; Jang J; Lee HJ; Lee YJ
    Biochem Biophys Res Commun; 2015 Jun; 462(2):138-43. PubMed ID: 25935484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
    Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
    J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
    Zhang M; Herion TW; Timke C; Han N; Hauser K; Weber KJ; Peschke P; Wirkner U; Lahn M; Huber PE
    Neoplasia; 2011 Jun; 13(6):537-49. PubMed ID: 21677877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
    Yahyanejad S; van Hoof SJ; Theys J; Barbeau LM; Granton PV; Paesmans K; Verhaegen F; Vooijs M
    Radiother Oncol; 2015 Sep; 116(3):467-72. PubMed ID: 26163089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
    Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
    Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
    El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
    Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sunitinib combined with ionizing radiation on endothelial cells.
    Zhang HP; Takayama K; Su B; Jiao XD; Li R; Wang JJ
    J Radiat Res; 2011; 52(1):1-8. PubMed ID: 21187670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
    Horgan AM; Darling G; Wong R; Guindi M; Liu G; Jonker DJ; Lister J; Xu W; MacKay HM; Dinniwell R; Kim J; Pierre A; Shargall Y; Asmis TR; Agboola O; Seely AJ; Ringash J; Wells J; Marginean EC; Haider M; Knox JJ
    Dis Esophagus; 2016 Nov; 29(8):1152-1158. PubMed ID: 26663741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.
    Chung C; Jalali S; Foltz W; Burrell K; Wildgoose P; Lindsay P; Graves C; Camphausen K; Milosevic M; Jaffray D; Zadeh G; Ménard C
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):805-12. PubMed ID: 22929856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
    Kao J; Chen CT; Tong CC; Packer SH; Schwartz M; Chen SH; Sung MW
    Target Oncol; 2014 Jun; 9(2):145-53. PubMed ID: 23660867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.
    Miki S; Imamichi S; Fujimori H; Tomiyama A; Fujimoto K; Satomi K; Matsushita Y; Matsuzaki S; Takahashi M; Ishikawa E; Yamamoto T; Matsumura A; Mukasa A; Nishikawa R; Masutomi K; Narita Y; Masutani M; Ichimura K
    Cancer Sci; 2018 Jul; 109(7):2275-2285. PubMed ID: 29758120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
    van Linde ME; Labots M; Brahm CG; Hovinga KE; De Witt Hamer PC; Honeywell RJ; de Goeij-de Haas R; Henneman AA; Knol JC; Peters GJ; Dekker H; Piersma SR; Pham TV; Vandertop WP; Jiménez CR; Verheul HMW
    Clin Cancer Res; 2022 Apr; 28(8):1595-1602. PubMed ID: 35165100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
    Farsaci B; Higgins JP; Hodge JW
    Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study.
    Stegen B; Nieto A; Albrecht V; Maas J; Orth M; Neumaier K; Reinhardt S; Weick-Kleemann M; Goetz W; Reinhart M; Parodi K; Belka C; Niyazi M; Lauber K
    Radiat Oncol; 2020 Jan; 15(1):19. PubMed ID: 31969174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.